Despite these observed differences , the effects of ticagrelor versus clopidogrel were not significantly different between Asians and non-Asians with respect to the primary efficacy outcome ( hazard ratio for Asians vs non-Asians , 0.84 [ 95 % CI 0.61-1 .17 ] vs 0.85 [ 95 % CI 0.77-0 .93 ] , P = .974 ) , net clinical benefit ( 0.85 [ 95 % CI 0.65-1 .11 ] vs 0.93 [ 95 % CI 0.86-0 .99 ] , P = .521 ) , or individual efficacy end points .